Corporate Headquarters (949) 238-6323

901 Calle Amanecer, Suite 150
San Clemente, CA  92673

©2019 by Epica International, Inc.

Executive Team

Epica International, Inc.

E  P i  C  A 


The future we see is non-contact imaging and robotic assistance.

Epica International, Inc. provides more precise procedures and better
quality imaging for safer operations and improved outcomes.

Meet The Team

Thomas Grossman

Chairman, Board of Directors

  • Grey LinkedIn Icon

Mr. Grossman presently runs Union Avenue Advisors LP, a company he founded in 2009, where he builds customized portfolios for separately managed accounts in the international markets. Prior to starting Union Avenue Advisors, Mr. Grossman was a portfolio manager at Ospraie Management, LLC from 2007 to 2008. He also established Aeneas Capital Management in 2000 and ran the business through 2008. Mr. Grossman’s extensive financial background includes positions as director of SAC International Equities LLC from 1997-2000, head of international trading for Kingdom Capital Management LLC from 1994-1997, international sales and trading desk at Goldman Sachs & Co from 1992-1994, analyst at Bridge Trading Co. from 1990-1992, and trader in equity options at Shearson Lehman Hutton from 1988-1990. Mr. Grossman graduated cum laude from Lehigh University, where he received a BS in finance.

Frank D. D'Amelio

CEO of Epica International, Director

  • Grey LinkedIn Icon

Mr. D’Amelio has over 29 years of medical device experience, 20 years of which at the level of CEO, President, CMO, CTO, and EVP. Mr. D’Amelio was a key contributor to ACMI’s growth from $27M to $185M via new products, acquisitions, and restructuring. He also co-led the sale of ACMI from Fox Paine & Co. to Gyrus Plc. for $500M, 18x EBITDA. As CEO of Ellman in 2 years he grew sales from $19M to $29M, changing the salesforce from convention-based to a direct salesforce focused on aesthetics and plastic surgery. He also led or was a key contributor to over 7 successful M&A deals, on both the buy and sell sides. Frank also has operational experience, directing the production activities of 5 facilities, with 700+ employees and increasing GP by 15% basis points over a 4-year period. Mr. D’Amelio has taken numerous products from inception through the FDA process and subsequently, onto commercial success. He is also named an inventor on 40 issued or pending medical patents. Mr. D’Amelio has a degree in electrical engineering and completed advanced training in finance and marketing.

Dr. Damiano Fortuna

President of Epica International, CEO & President of Imaginalis, Director

  • Grey LinkedIn Icon

Dr. Fortuna is president of Epical International as well as CEO and president of Imaginalis S.r.l, the manufacturer of Epica’s HDCT products. Prior to Epica, Dr. Fortuna served as the executive director of the PhotoBioLab research unit of El.En. s.p.a., the market leader in laser research and manufacturing for medical and industrial applications. Dr. Fortuna spent seventeen years in veterinary practice and twelve years in basic and applied veterinary medical research of laser surgery and therapy with El.En. s.p.a. He received his degree in veterinary medicine from University of Pisa and completed postdoctoral training through various universities in Europe, where he focused on Italian veterinary medicine, food hygiene, public health, and innovative microscopy for biotechnology.

Dr. Renzo Valleggi

Chief Technology Officer of

Epica International, Director

  • Grey LinkedIn Icon

Dr. Valleggi is a founder, board chair, and chief executive officer of Gruppo Scienzia Machinale S.r.l. An accomplished mechanical engineer, he has worked in the research, development, and robotics department of Scienzia Machinale (the first spin-off of the Scuola Superiore Sant’Anna in Pisa) since 1992. Dr. Valleggi spent more than fifteen years developing innovative products for defense, healthcare, and domestic appliances within the industrial automation sectors. Dr. Valleggi is the author of several patents and holds a Ph.D. in the mechanics of materials from the University of Pisa.

Dan McMahon

Senior Vice President of Worldwide

Sales, Epica International

  • Grey LinkedIn Icon

Dan McMahon is Epica's Senior 

Vice President of Worldwide Sales covering Epica's human health, animal health and robotics' portfolios.  In his extensive 24 year medical device career, Dan has successfully launched 14 human imaging platforms, numerous medical devices and has extensive knowledge of advanced minimally invasive surgery and medical imaging systems.  Prior to Epica, Dan held senior sales management and GM positions at Karl Storz and Olympus where he led sales and commercialization and consistently exceeded sales expectations. As the General Manager for KARL STORZ and the West Area Vice President of Sales for Olympus Medical, Mr. McMahon has spent the last 24 years focused on medical imaging. He has collaborated closely with both the R&D and Marketing teams to validate and test new medical device products. 

Daniel Naimey

Senior Vice President Business Development, Strategy & Marketing

  • Grey LinkedIn Icon

Daniel Naimey serves as Epica International’s Senior Vice President, Business Development, Market Development and Strategy.  Mr. Naimey focuses on development and global expansion of Epica's HDVI CT Imaging Platforms and surgical robotics technologies into the human healthcare market.  He also provides marketing and analytical support for the company’s Human CT, Robotics and software ecosystem program development.  Mr. Naimey's prior experience includes management positions at Stryker and Covidien, where he led endo-mechanical business development/M&A and held a GM role in the company's global sports medicine business. He was also the business development/M&A lead for the Surgical Solutions' Advanced MIS Group, driving inorganic and new product development and revenue growth from the company's 2007 IPO to its acquisition by Medtronic in 2015. Daniel has an extensive knowledge of advanced minimally invasive surgery, diagnostic and intraoperative imaging and surgical robotics.  He facilitated the acquisition of numerous med device companies, robotic surgery assets, and initiated Covidien's move into non-invasive surgery systems for lung cancer diagnostics. He has launched and branded medical devices globally.